{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:16Z","timestamp":1791041896246,"version":"4.1.0"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:p>For pediatric patients with hepatocyte nuclear factor-1A (HNF1A)\u2013maturity-onset diabetes of the young (MODY 3), treatment with sulfonylureas is recommended. In adults with HNF1A-MODY, meglitinide analogues achieve lower postprandial glucose levels and pose a lower risk of delayed hypoglycemia compared with sulfonylureas. This therapy has not yet been reviewed in pediatric patients. We report on meglitinide analogue treatment in 3 adolescents with HNF1A-MODY. Case 1 (14-year-old girl) was diagnosed asymptomatically but had an hemoglobin A1c (HbA1c) level of 7.4%; her father had been recently diagnosed with HNF1A-MODY. With repaglinide, her HbA1c level decreased to 5.5%, with no hypoglycemic episodes. Case 2 (14-year-old boy) was diagnosed incidentally with glucosuria (HbA1c level: 7.0%) and was treated with insulin. After the HNF1A-MODY diagnosis, he was switched to glibenclamide. Due to several hypoglycemic episodes, treatment was changed to nateglinide and his HbA1c level decreased to 6.2% with no further hypoglycemic episodes. Case 3 (11-year-old girl) presented with polyuria and polydipsia (HbA1c level: 10.1%) and was initially treated with insulin. After the HNF1A-MODY diagnosis, treatment was changed to repaglinide. She was obese (BMI: 28.8 kg\/m2; z-score: +2.2), and glucose control with repaglinide alone was insufficient. Therefore, neutral protamine Hagedorn insulin (0.27 U\/kg per day) was added. With this combination therapy, her HbA1c level decreased to 8.2%. The use of meglitinides in these 3 adolescent patients was well tolerated and effective. Furthermore, hypoglycemic episodes were rare compared with treatment with insulin or sulfonylureas. We therefore suggest considering meglitinides as the primary oral treatment option for adolescents suffering from HNF1A-MODY.<\/jats:p>","DOI":"10.1542\/peds.2012-2537","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T02:19:49Z","timestamp":1393294789000},"page":"e775-e779","source":"Crossref","is-referenced-by-count":45,"title":["Meglitinide Analogues in Adolescent Patients With HNF1A-MODY (MODY 3)"],"prefix":"10.1542","volume":"133","author":[{"given":"Marianne","family":"Becker","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetology, Charit\u00e9 University Children\u2019s Hospital, Berlin, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Galler","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetology, Charit\u00e9 University Children\u2019s Hospital, Berlin, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Raile","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetology, Charit\u00e9 University Children\u2019s Hospital, Berlin, Germany; and"},{"name":"Experimental and Clinical Research Center, Joint Cooperation with the Charit\u00e9 Medical Faculty, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"issue":"5","key":"2021120903520772800_B1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1464-5491.2009.02720.x","article-title":"Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database.","volume":"26","author":"Schober","year":"2009","journal-title":"Diabet Med"},{"issue":"6608","key":"2021120903520772800_B2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/384455a0","article-title":"Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)","volume":"384","author":"Yamagata","year":"1996","journal-title":"Nature"},{"issue":"6","key":"2021120903520772800_B3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/eje.0.1410609","article-title":"Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with hepatic nuclear factor-1alpha (maturity-onset diabetes of the young-3) mutations.","volume":"141","author":"Vaxillaire","year":"1999","journal-title":"Eur J Endocrinol"},{"issue":"5662","key":"2021120903520772800_B4","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1126\/science.1089769","article-title":"Control of pancreas and liver gene expression by HNF transcription factors.","volume":"303","author":"Odom","year":"2004","journal-title":"Science"},{"issue":"4","key":"2021120903520772800_B5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001250050931","article-title":"Chronic diabetic complications in patients with MODY3 diabetes.","volume":"41","author":"Isomaa","year":"1998","journal-title":"Diabetologia"},{"issue":"4","key":"2021120903520772800_B6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/diab.46.4.726","article-title":"Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation.","volume":"46","author":"Hansen","year":"1997","journal-title":"Diabetes"},{"key":"2021120903520772800_B7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-5448.2009.00571.x","article-title":"The diagnosis and management of monogenic diabetes in children and adolescents.","volume":"10","author":"Hattersley","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"2021120903520772800_B8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus.","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"issue":"9294","key":"2021120903520772800_B9","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0140-6736(01)06715-0","article-title":"Insulinotropic meglitinide analogues.","volume":"358","author":"Dornhorst","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"2021120903520772800_B10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2165\/00003495-200161110-00008","article-title":"Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.","volume":"61","author":"Culy","year":"2001","journal-title":"Drugs"},{"issue":"8","key":"2021120903520772800_B11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diacare.25.8.1271","article-title":"Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.","volume":"25","author":"Cozma","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"2021120903520772800_B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00592-006-0203-9","article-title":"Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study","volume":"43","author":"Marshall","year":"2006","journal-title":"Acta Diabetol"},{"issue":"2","key":"2021120903520772800_B13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diacare.29.02.06.dc05-1314","article-title":"Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.","volume":"29","author":"Tuomi","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"2021120903520772800_B14","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1007\/s001250051558","article-title":"Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state.","volume":"43","author":"Tripathy","year":"2000","journal-title":"Diabetologia"},{"issue":"8","key":"2021120903520772800_B15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/0006-2952(89)90327-4","article-title":"Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.","volume":"38","author":"Panten","year":"1989","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2021120903520772800_B16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/jpet.107.123224","article-title":"Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.","volume":"322","author":"Winkler","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"5940","key":"2021120903520772800_B17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.1172256","article-title":"The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.","volume":"325","author":"Zhang","year":"2009","journal-title":"Science"},{"key":"2021120903520772800_B18","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.2337\/diabetes.51.2007.S343","article-title":"Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).","volume":"51","author":"Boileau","year":"2002","journal-title":"Diabetes"},{"issue":"12","key":"2021120903520772800_B19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","article-title":"The role of sulphonylureas in the management of type 2 diabetes mellitus.","volume":"64","author":"Rendell","year":"2004","journal-title":"Drugs"},{"issue":"9","key":"2021120903520772800_B20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-2007-979838","article-title":"Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.","volume":"28","author":"Kramer","year":"1996","journal-title":"Horm Metab Res"},{"issue":"6","key":"2021120903520772800_B21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0029-1212125","article-title":"Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.","volume":"107","author":"Raptis","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"2021120903520772800_B22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1530\/EJE-10-0842","article-title":"Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database.","volume":"164","author":"Awa","year":"2011","journal-title":"Eur J Endocrinol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/3\/e775\/1099142\/peds_2012-2537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/3\/e775\/1099142\/peds_2012-2537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T19:46:59Z","timestamp":1639079219000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/133\/3\/e775\/32306\/Meglitinide-Analogues-in-Adolescent-Patients-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2012-2537","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}